Abstract

There is currently great interest in developing mucosal vaccines against a variety of microbial pathogens. Vaccine delivery systems can target respiratory or intestinal mucosal tissue and stimulate immune response and be particularly effective against these infections. In a healthy human adult, mucosal immune system contributes almost 80% of all immunocytes. The administration of mucosal vaccines does not require the use of needles, increasing vaccine compliance, reducing logistical burden, and minimizing the risks of blood transmissible infections.The primary reason for using a mucosal route of vaccination is that most infections affect or start from mucosal surfaces and that in these infections, topical application of a vaccine is often required to induce a protective immune response both innate and adaptive at the site of pathogen entry. Immunoprophylaxis by the mucosal route is an important approach to controlling mucosally acquired infections. The ability to induce a balanced systemic and secretory immune response following immunization is determined by a complex set of interacting factors. These include the nature of the antigens and route of administration, the nature of the mucosal microenvironment, the immunologic vehicles employed for vaccine delivery, and the effects of bystander immunologic and antigen-related events occurring concurrently in the mucosal environment.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.